The FDA has missed the deadline for making a key decision regarding a Novavax (NVAX.US) Covid-19 vaccine, days after the Food and Drug Administration’s vaccine chief was pushed out. Novavax’s application needed more data and was unlikely to be approved soon - was said by people familiar with a matter, citted by WSJ.
This information is seriously damaging the sentiment around the company and is undermining its current ability to maintain its business system. The shares are losing over 1.5%, although at one point the declines were as high as 4%.
Source: xStation
Daily summary: Silver plunges 9% 🚨Indices, crypto and precious metals under pressure
Does the current sell-off signal the end of quantum companies?
Howmet Aerospace surges 10% after earnings reaching $100 bilion market cap 📈
US Open: Cisco Systems slides 10% after earnings 📉 Mixed sentiments on Wall Street